Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, revenue was PLN 161.68 million compared to PLN 139.8 million a year ago. Net loss was PLN 13.16 million compared to PLN 27.29 million a year ago. Basic loss per share from continuing operations was PLN 0.257656 compared to PLN 0.53 a year ago. Diluted loss per share from continuing operations was PLN 0.257656 compared to PLN 0.53 a year ago.